Major tuberculosis vaccine trial completes enrollment faster than expected
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of expectations.
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of expectations.
The Phase 3 study of the M72/AS01E vaccine, which is taking place at 54 sites across five countries, started delivering shots to volunteers last March. While its sponsors had originally said it may take up to two years to complete enrollment, they announced Monday that the sites in South Africa, Kenya, Malawi, Zambia, and Indonesia have successfully recruited the 20,000 participants needed for the study.
